FibroGen Inc at Citi BioPharma Conference (Virtual) Transcript
Hi, everyone. Thanks for joining the session with FibroGen. I'm pleased to have with us the CEO, Enrique Conterno. Enrique, thanks for joining us today.
No, thank you very much, Joe. I very much appreciate the invitation. Look forward to discussing a number of topics.
Yes. Great. So I guess, I think a lot of viewers are going to be familiar with FibroGen, but some may not. So could you begin with an overview of what the key areas of focus are for FibroGen?
Sure. So FibroGen is a company very much based in science. We've been able to progress 2 key products, one of them, roxadustat. The second one, pamrevlumab, which are very much in late stages. Roxa has already been commercialized in China and Japan and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
